Thanda Han Ma Ai, Pyrsopoulos Nikolaos
Division of Gastroenterology and Hepatology, Rutgers New Jersey Medical School, 185 South Orange Avenue, H-526, Newark, NJ 07103, USA.
Division of Gastroenterology and Hepatology, Rutgers New Jersey Medical School, 185 South Orange Avenue, H-536, Newark, NJ 07103, USA.
Clin Liver Dis. 2021 Aug;25(3):603-624. doi: 10.1016/j.cld.2021.03.006. Epub 2021 May 28.
The incidence of alcoholic hepatitis is increasing while the mortality rate remains high. The single current available therapy for severe alcoholic hepatitis is administration of corticosteroids for patients with severe alcoholic hepatitis, which has demonstrated limited benefits, providing a short-term mortality benefit with a marginal response rate. There is a need for developing safe and effective therapies. This article reviews novel therapies targeting various mechanisms in the pathogenesis of alcoholic hepatitis, such as the gut-liver axis, inflammatory cascade, oxidative stress, and hepatic regeneration. Current ongoing clinical trials for alcoholic hepatitis also are described.
酒精性肝炎的发病率在上升，而死亡率仍然很高。目前针对严重酒精性肝炎唯一可用的疗法是对严重酒精性肝炎患者使用皮质类固醇，但其益处有限，仅能提供短期死亡率益处且缓解率很低。因此需要开发安全有效的疗法。本文综述了针对酒精性肝炎发病机制中各种机制的新疗法，如肠-肝轴、炎症级联反应、氧化应激和肝再生。文中还介绍了目前正在进行的酒精性肝炎临床试验。
